Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

Quality of life scores demonstrate prognostic value in ovarian cancer

06 Jul 2017

Quality of life (QoL) scores, particularly in the domains of physical function and abdominal/gastrointestinal symptom, provide additional prognostic information to survival prediction in platinum-resistant ovarian cancer, according to a study.

Researchers used data from the AURELIA study involving 326 patients randomized to receive chemotherapy with or without bevacizumab to identify baseline QoL domains (EORTC QLQ-C30 and OV28) significantly associated with overall survival. Risk categories for physical function and abdominal/gastrointestinal symptom were defined as good, medium or low.

Univariable analysis showed that all domains, with the exception of cognitive function, predicted overall survival, but only physical function and abdominal/gastrointestinal symptom scores remained significantly associated with survival in multivariable models (p<0.001 for both).

In patients with high (score <67), medium (67 to 93) and low (>93) risk categories for physical function, the respective median overall survival was 11.0, 14.7 and 19.3 months (p<0.001). In an independent cohort (CARTAXHY; n=136), the corresponding median overall survival was 7.9, 16.2 and 23.9 months (p<0.001).

In patients with high (>44), medium (13 to 44) and low (<13) risk categories for abdominal/gastrointestinal symptoms, the respective median overall survival was 11.9, 14.3 and 19.7 months in the AURELIA cohort (p<0.001) and 10.5, 19.6 and 24.1 months in CARTAXHY (p=0.02).

Physical function (p=0.02) and abdominal/gastrointestinal symptoms (p=0.03) remained independent prognostic factors for overall survival after controlling for clinicopathologic factors. The C-statistic of the full model was 0.71. Separately, the respective C-statistics for quality of life factors, patient factors and disease factors were 0.61, 0.61 and 0.67.

The present data indicate that physical function and abdominal/gastrointestinal symptom scores can improve predictions of overall survival in platinum-resistant ovarian cancer when compared with clinicopathologic factors alone.

Researchers said the additional prognostic information could improve trial stratification, patient-doctor communication about prognosis and clinical decision making.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.